Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2001 Jun;70(6):744–748. doi: 10.1136/jnnp.70.6.744

Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease

A Green 1, E Thompson 1, G Stewart 1, M Zeidler 1, J McKenzie 1, M MacLeod 1, J Ironside 1, R Will 1, R Knight 1
PMCID: PMC1737395  PMID: 11385008

Abstract

OBJECTIVES—The detection of the protein 14-3-3 in the CSF has been shown to be a reliable and sensitive marker for sporadic Creutzfeldt-Jakob disease (CJD). Other brain-specific proteins such as neuron specific enolase (NSE), S-100b, and tau protein have also been reported to be increased in the CSF of patients with sporadic CJD. In 1996a variant of CJD (vCJD) was described which is likely to be causally linked to the bovine spongiform encephalopathy agent. This study reports and compares the findings of CSF brain specific protein analysis in 45 patients with vCJD and in 34 control patients.
METHODS—The CSF from 45 patients with vCJD and 34 controls were investigated for the presence of 14-3-3 by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting with chemiluminescent detection. Tau protein, S-100b, and NSE concentrations in CSF were measured using enzyme immunoassays.
RESULTS—Protein 14-3-3 was detected in the CSF of 22/45 patients with vCJD and in 3/34 controls. The mean concentrations of NSE, S-100b, and tau protein in CSF were significantly raised in patients with vCJD compared with controls. The positive predictive value of CSF 14-3-3 was 86% and the negative predictive value was 63%. These values are lower than those reported for sporadic CJD. An increased CSF tau had a positive predictive value of 93% and a negative predictive value of 81%. The combination of CSF 14-3-3 and/or increased CSF tau had a positive predictive value of 91% and a negative predictive value of 84%.
CONCLUSIONS—CSF protein 14-3-3 is not as useful a marker for vCJD as it is for sporadic CJD. Increased concentration of CSF tau was found to be a sensitive marker of vCJD but as concentrations may be increased in many forms of non-CJD dementia, this may limit its usefulness as a diagnostic test.



Full Text

The Full Text of this article is available as a PDF (121.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., Räihä I., Sourander L., Winblad B., Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):298–305. doi: 10.1136/jnnp.64.3.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C. M., Miura M., Machida N., Lee V. M., Trojanowski J. Q., Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997 Jul 18;236(2):262–264. doi: 10.1006/bbrc.1997.6908. [DOI] [PubMed] [Google Scholar]
  3. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C. M., Lee V. M. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):649–652. doi: 10.1002/ana.410380414. [DOI] [PubMed] [Google Scholar]
  4. Beaudry P., Cohen P., Brandel J. P., Delasnerie-Lauprêtre N., Richard S., Launay J. M., Laplanche J. L. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord. 1999 Jan-Feb;10(1):40–46. doi: 10.1159/000017095. [DOI] [PubMed] [Google Scholar]
  5. Brandel J. P., Delasnerie-Lauprêtre N., Laplanche J. L., Hauw J. J., Alpérovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology. 2000 Mar 14;54(5):1095–1099. doi: 10.1212/wnl.54.5.1095. [DOI] [PubMed] [Google Scholar]
  6. Collins S., Boyd A., Fletcher A., Gonzales M., McLean C. A., Byron K., Masters C. L. Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci. 2000 May;7(3):203–208. doi: 10.1054/jocn.1999.0193. [DOI] [PubMed] [Google Scholar]
  7. Cousens S. N., Zeidler M., Esmonde T. F., De Silva R., Wilesmith J. W., Smith P. G., Will R. G. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. BMJ. 1997 Aug 16;315(7105):389–395. doi: 10.1136/bmj.315.7105.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Galasko D., Clark C., Chang L., Miller B., Green R. C., Motter R., Seubert P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 1997 Mar;48(3):632–635. doi: 10.1212/wnl.48.3.632. [DOI] [PubMed] [Google Scholar]
  9. Green A. J., Harvey R. J., Thompson E. J., Rossor M. N. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett. 1997 Oct 10;235(1-2):5–8. doi: 10.1016/s0304-3940(97)00701-5. [DOI] [PubMed] [Google Scholar]
  10. Green A. J., Keir G., Thompson E. J. A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods. 1997 Jun 23;205(1):35–41. doi: 10.1016/s0022-1759(97)00050-1. [DOI] [PubMed] [Google Scholar]
  11. Hernández Echebarría L. E., Saiz A., Graus F., Tejada J., García J. M., Clavera B., Fernández F. Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. Neurology. 2000 Apr 11;54(7):1539–1540. doi: 10.1212/wnl.54.7.1539. [DOI] [PubMed] [Google Scholar]
  12. Hsich G., Kenney K., Gibbs C. J., Lee K. H., Harrington M. G. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med. 1996 Sep 26;335(13):924–930. doi: 10.1056/NEJM199609263351303. [DOI] [PubMed] [Google Scholar]
  13. Irani D. N., Kerr D. A. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet. 2000 Mar 11;355(9207):901–901. doi: 10.1016/S0140-6736(99)04745-5. [DOI] [PubMed] [Google Scholar]
  14. Ironside J. W. Neuropathological findings in new variant CJD and experimental transmission of BSE. FEMS Immunol Med Microbiol. 1998 Jun;21(2):91–95. doi: 10.1111/j.1574-695X.1998.tb01153.x. [DOI] [PubMed] [Google Scholar]
  15. Jimi T., Wakayama Y., Shibuya S., Nakata H., Tomaru T., Takahashi Y., Kosaka K., Asano T., Kato K. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta. 1992 Oct 15;211(1-2):37–46. doi: 10.1016/0009-8981(92)90103-w. [DOI] [PubMed] [Google Scholar]
  16. Kropp S., Zerr I., Schulz-Schaeffer W. J., Riedemann C., Bodemer M., Laske C., Kretzschmar H. A., Poser S. Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1999 Feb 12;261(1-2):124–126. doi: 10.1016/s0304-3940(98)00992-6. [DOI] [PubMed] [Google Scholar]
  17. Lemstra A. W., van Meegen M. T., Vreyling J. P., Meijerink P. H., Jansen G. H., Bulk S., Baas F., van Gool W. A. 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology. 2000 Aug 22;55(4):514–516. doi: 10.1212/wnl.55.4.514. [DOI] [PubMed] [Google Scholar]
  18. Mitani K., Furiya Y., Uchihara T., Ishii K., Yamanouchi H., Mizusawa H., Mori H. Increased CSF tau protein in corticobasal degeneration. J Neurol. 1998 Jan;245(1):44–46. doi: 10.1007/s004150050173. [DOI] [PubMed] [Google Scholar]
  19. Mokuno K., Kato K., Kawai K., Matsuoka Y., Yanagi T., Sobue I. Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci. 1983 Aug-Sep;60(3):443–451. doi: 10.1016/0022-510x(83)90155-7. [DOI] [PubMed] [Google Scholar]
  20. Otto M., Stein H., Szudra A., Zerr I., Bodemer M., Gefeller O., Poser S., Kretzschmar H. A., Mäder M., Weber T. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol. 1997 Sep;244(9):566–570. doi: 10.1007/s004150050145. [DOI] [PubMed] [Google Scholar]
  21. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., Weber T., Kretzschmar H. A., Poser S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997 Apr 11;225(3):210–212. doi: 10.1016/s0304-3940(97)00215-2. [DOI] [PubMed] [Google Scholar]
  22. Persson L., Hårdemark H. G., Gustafsson J., Rundström G., Mendel-Hartvig I., Esscher T., Påhlman S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987 Sep-Oct;18(5):911–918. doi: 10.1161/01.str.18.5.911. [DOI] [PubMed] [Google Scholar]
  23. Saiz A., Graus F., Dalmau J., Pifarré A., Marin C., Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol. 1999 Nov;46(5):774–777. [PubMed] [Google Scholar]
  24. Steinhoff B. J., Räcker S., Herrendorf G., Poser S., Grosche S., Zerr I., Kretzschmar H., Weber T. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol. 1996 Feb;53(2):162–166. doi: 10.1001/archneur.1996.00550020074017. [DOI] [PubMed] [Google Scholar]
  25. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J. J., Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993 Nov;61(5):1828–1834. doi: 10.1111/j.1471-4159.1993.tb09823.x. [DOI] [PubMed] [Google Scholar]
  26. Will R. G., Ironside J. W., Zeidler M., Cousens S. N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., Smith P. G. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996 Apr 6;347(9006):921–925. doi: 10.1016/s0140-6736(96)91412-9. [DOI] [PubMed] [Google Scholar]
  27. Will R. G., Ironside J. W., Zeidler M., Cousens S. N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., Smith P. G. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996 Apr 6;347(9006):921–925. doi: 10.1016/s0140-6736(96)91412-9. [DOI] [PubMed] [Google Scholar]
  28. Will R. G., Zeidler M., Stewart G. E., Macleod M. A., Ironside J. W., Cousens S. N., Mackenzie J., Estibeiro K., Green A. J., Knight R. S. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol. 2000 May;47(5):575–582. [PubMed] [Google Scholar]
  29. Zeidler M., Johnstone E. C., Bamber R. W., Dickens C. M., Fisher C. J., Francis A. F., Goldbeck R., Higgo R., Johnson-Sabine E. C., Lodge G. J. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet. 1997 Sep 27;350(9082):908–910. doi: 10.1016/s0140-6736(97)03148-6. [DOI] [PubMed] [Google Scholar]
  30. Zeidler M., Stewart G. E., Barraclough C. R., Bateman D. E., Bates D., Burn D. J., Colchester A. C., Durward W., Fletcher N. A., Hawkins S. A. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet. 1997 Sep 27;350(9082):903–907. doi: 10.1016/s0140-6736(97)07472-2. [DOI] [PubMed] [Google Scholar]
  31. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., Windl O., Kretzschmar H. A., Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol. 1998 Jan;43(1):32–40. doi: 10.1002/ana.410430109. [DOI] [PubMed] [Google Scholar]
  32. Zerr I., Bodemer M., Räcker S., Grosche S., Poser S., Kretzschmar H. A., Weber T. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet. 1995 Jun 24;345(8965):1609–1610. doi: 10.1016/s0140-6736(95)90118-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES